Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells

1 Feb 2011

Abstract excerpt

ET-743 (trabectedin; Yondelis) is approved in Europe for the treatment of soft tissue sarcomas. Emerging phase 1 and 2 clinical data have shown high response rates in myxoid liposarcoma in part owing to the inhibition of the FUS-CHOP transcription factor. In this report, we show that modulation of specific oncogenic transcription factors by ET-743 may extend to other tumor types. We demonstrate that, among a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Molecular Biology Techniques and Applications
Share to Sarcoma Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 21403840
DOI: 10.1593/neo.101202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma CellsPMID 21403840Read ↗

Seclidemstat blocks the transcriptional function of multiple FET-fusion oncoproteinsSemantic proximity Read ↗

EWS/FLI1 Characterization, Activation, Repression, Target Genes and Therapeutic Opportunities in Ewing SarcomaSemantic proximity Read ↗

Identification of an Inhibitor of the EWS-FLI1 Oncogenic Transcription Factor by High-Throughput ScreeningSemantic proximity Read ↗

Regulation of EWSR1-FLI1 Function by Post-Transcriptional and Post-Translational ModificationsSemantic proximity Read ↗

EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing SarcomaSemantic proximity Read ↗

NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.Semantic proximity Read ↗

Identification of effective new drugs combinations exploiting the ability of trabectedin to modulate transcriptionSemantic proximity Read ↗

SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing SarcomaSemantic proximity Read ↗

The importance of fusion protein activity in Ewing sarcoma and the cell intrinsic and extrinsic factors that regulate it: A reviewSemantic proximity Read ↗

Ewing sarcoma fusion oncogene: At the crossroads of transcription and DNA damage responseSemantic proximity Read ↗

Identification of a novel FUS/ETV4 fusion and comparative analysis with other Ewing sarcoma fusion proteinsSemantic proximity Read ↗

Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor GrowthSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.